encouraging but large-cap weakness limits breakout above 160.
XLV shows some encouraging signs but lacks enough large-cap healthcare strength to break decisively above 160.
Small biotech names show strength, but large-cap healthcare stocks that dominate XLV may not provide enough power to push through the 160 resistance meaningfully.